Campylobacter jejuni Type VI Secretion System: Roles in Adaptation to Deoxycholic Acid, Host Cell Adherence, Invasion, and In Vivo Colonization by Lertpiriyapong, Kvin et al.
Campylobacter jejuni Type VI Secretion System: Roles in
Adaptation to Deoxycholic Acid, Host Cell Adherence,
Invasion, and In Vivo Colonization
Kvin Lertpiriyapong1, Eric R. Gamazon2, Yan Feng1, Danny S. Park3, Jassia Pang1, Georgina Botka1,
Michelle E. Graffam1, Zhongming Ge1*, James G. Fox1*
1Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America, 2 Section of Genetic Medicine,
Department of Medicine, The University of Chicago, Chicago, Illinois, United States of America, 3Department of Computer Science, Columbia University, New York, New
York, United States of America
Abstract
The recently identified type VI secretion system (T6SS) of proteobacteria has been shown to promote pathogenicity,
competitive advantage over competing microorganisms, and adaptation to environmental perturbation. By detailed
phenotypic characterization of loss-of-function mutants, in silico, in vitro and in vivo analyses, we provide evidence that the
enteric pathogen, Campylobacter jejuni, possesses a functional T6SS and that the secretion system exerts pleiotropic effects
on two crucial processes – survival in a bile salt, deoxycholic acid (DCA), and host cell adherence and invasion. The
expression of T6SS during initial exposure to the upper range of physiological levels of DCA (0.075%–0.2%) was detrimental
to C. jejuni proliferation, whereas down-regulation or inactivation of T6SS enabled C. jejuni to resist this effect. The C. jejuni
multidrug efflux transporter gene, cmeA, was significantly up-regulated during the initial exposure to DCA in the wild type
C. jejuni relative to the T6SS-deficient strains, suggesting that inhibition of proliferation is the consequence of T6SS-
mediated DCA influx. A sequential modulation of the efflux transporter activity and the T6SS represents, in part, an adaptive
mechanism for C. jejuni to overcome this inhibitory effect, thereby ensuring its survival. C. jejuni T6SS plays important roles
in host cell adhesion and invasion as T6SS inactivation resulted in a reduction of adherence to and invasion of in vitro cell
lines, while over-expression of a hemolysin co-regulated protein, which encodes a secreted T6SS component, greatly
enhanced these processes. When inoculated into B6.129P2-IL-10tm1Cgn mice, the T6SS-deficient C. jejuni strains did not
effectively establish persistent colonization, indicating that T6SS contributes to colonization in vivo. Taken together, our
data demonstrate the importance of bacterial T6SS in host cell adhesion, invasion, colonization and, for the first time to our
knowledge, adaptation to DCA, providing new insights into the role of T6SS in C. jejuni pathogenesis.
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Introduction
Of the diverse arsenals that have been developed by
proteobacteria, the recently identified type VI secretion system
(T6SS) has proven to be functionally versatile [1,2]. Not only does
it promote pathogenicity, symbiotic relationships and a selective
advantage among competing microbes, it also plays a pivotal role
in the adaptation to environmental perturbation [1]. Since its
discovery, T6SS gene clusters have been identified in over 25% of
the known proteobacteria [3]. These bacteria have a remarkable
range of colonization niches, including the soil, the marine
environment, plants, invertebrates, vertebrates, and mammals [4–
6]. T6SS consists of at least thirteen components that form
injectisomes structurally resembling an upside-down Escherichia coli
bacteriophage T4 [3,7,8]. In Salmonella enterica serotypes Galli-
narum and Enteritidis, the T6SS enhances the ability of the
bacteria to colonize the gastrointestinal tract of chickens [9]. In
Helicobacter hepaticus, the T6SS enables the bacteria to establish
non-pathogenic, symbiotic relationship in the gastrointestinal tract
of mice by modulating the bacteria’s virulence potential and the
mouse’s immune responses [10]. The pathogenic properties of
T6SS have also been demonstrated in human pathogens, such as
Pseudomonas aeruginosa and Francisella tularensis [11,12]. Moreover,
T6SS has been implicated in adaptation to high osmolarity and
low temperature [13], quorum and stress sensing [11,14,15],
bacterial growth and motility [16], biofilm formation [17], and
destruction of competing bacteria and protozoa through secretion
of toxic effector proteins [18,19].
Campylobacter jejuni, a gram-negative and spiral-shaped micro-
aerophilic bacterium, is a leading cause of human food-borne
enterocolitis worldwide with approximately 400 million cases
diagnosed each year [20]. Additionally, C. jejuni infection can result
in debilitating extraintestinal complications including immune
mediated polyarthritis and paralyzing autoimmune neuropathies–
Guillain-Barre´ syndrome and Miller Fisher syndrome [21]. To
date, over 10,000 isolates of C. jejuni, showing a considerable
degree of genetic variability and pathogenic potential, have been
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identified and categorized (http://pubmlst.org/campylobacter).
Analyses of 17 completed and partially completed genomic
sequences of Campylobacter deposited in the European Bioinfor-
matic Institute (EBI) or the National Center for Biotechnology
Information (NCBI) performed by our laboratory revealed that
select strains of C. jejuni and Campylobacter spp. contain unique
clusters of T6SS core orthologs capable of forming a fully
functional secretion apparatus. Proteins homologous to known
components of T6SS were detected in C. concisus, indicating the
presence of a functional T6SS in this bacterium [22]. Based on this
finding and recognizing the known function of T6SS in other
proteobacteria, we hypothesized that C. jejuni contains a functional
T6SS and that the secretion system may provide the bacteria
niche-specific adaptive capacities and/or enhance their pathogenic
potential. To test this hypothesis, we created and characterized,
using in vitro and in vivo analyses, a series of isogenic mutants that
are defective in two highly conserved core T6SS orthologs– icmF
(intracellular multiplication F) and hcp (hemolysin co-regulated protein) [3] –
from a human clinical isolate, C. jejuni ATCC 43431. Hcp either
forms a structural component similar to the gp27 component of
the cell puncturing device of bacteriophage T4, or serves as a
secreted effector protein that modulates host actin cytoskeleton
rearrangement or cytokine production [7,23]. IcmF is a structural
transmembrane component required for secretion and assembly of
Hcp and other T6SS constituents [3,24].
Results
C. jejuni T6SS consists of a unique set of core and
accessory components fully capable of secreting Hcp
Most known T6SSs of proteobacteria consist of at least 13 core
genes [3,7]. Our in silico analyses (see Materials and Methods)
revealed that a similar cluster of 13 genes were present in 2 of 14
strains of C. jejuni analyzed (Figure 1) – C. jejuni ATCC 43431,
which was isolated from a diarrheic human patient, as well as C.
jejuni 414, isolated from bank voles [25,26]. Furthermore, 6 T6SS
orthologs were identified in the partially-sequenced genome of a
human clinical isolate, C. jejuni BH-01-014 [27]. Putative T6SS
gene clusters were also identified in C. coli RM2228, C. concisus
13826, and C. rectus RM3267 (Figure 1). Twelve of 13 genes
identified in the T6SS-positive C. jejuni strains exhibited high
sequence similarity to genes that were considered core genes of
T6SS, whereas a single gene, COG3456, was considered an
accessory gene [3]. The list of these orthologs, with the
corresponding Cluster of Orthologous Groups (COG) identifica-
tion number and their potential functions, is presented in Table 1.
Despite the presence of 13 T6SS genes, a gene encoding a core
component, ClpV, which is present in the majority of previously
characterized T6SS [3], was absent from the T6SS gene clusters of
C. jejuni and Campylobacter spp. analyzed (Table 1).
The initial effort to sequence the genome of C. jejuni 43431
identified 11 conserved genes of T6SS [25]. However, COG3516
and COG3520 that are present in most of the Campylobacter spp.
examined were not detected. To detect the two orthologs via
polymerase chain reaction (PCR) amplification in C. jejuni 43431, a
set of primers was designed based on COG3516 and COG3520
sequences of C. coli RM2228. The amplicons produced were of the
expected size. Subsequently, COG3516 and COG3520 were
verified by DNA sequencing, reconfirming their presence in C.
jejuni 43431 (Table 1).
By in silico comparison of putative T6SS gene clusters among
Campylobacter spp. as well as PCR and DNA sequencing, we
determined that 12 core genes and the single accessory gene of C.
jejuni 43431 are tightly linked and clustered in a discrete region of
the genome (Figure 1). While the organization of certain core
genes is highly conserved, the arrangement of others varies
considerably among Campylobacter spp. (Figure 1). Interestingly, the
arrangement of T6SS in C. jejuni 43431 is the exact replica of that
in C. coli RM2228. However, genes within the T6SS cluster of C.
jejuni 414 have undergone extensive rearrangement, resulting in
noticeable differences in the T6SS cluster of this strain and C. jejuni
43431.
Within the T6SS clusters of C. jejuni and C. coli RM2228, five
genes appear to form two distinct operons: icmF and its
downstream gene, COG3456, as well as COG3517, COG3518,
and COG3519. The coding sequences of the genes comprising
each putative operon are arranged in the same orientation and
their stop and start codons overlap with each other, indicating that
these genes may utilize the same promoter and are co-transcribed.
The rest of the genes within the cluster including hcp and vrgG
appear to be stand-alone transcriptional units (Figure 1). In C. jejuni
43431 and C. coli RM2228, hcp is flanked on one side by the
putative icmF/COG3456 operon and on the other side by
COG3455, COG3521, and COG3522, all encoding the T6SS
core components (Figure 1).
As previously mentioned, hcp and icmF are highly conserved and
are essential components of T6SS [3]. Therefore, these genes were
deleted in C. jejuni 43431 and the resulting mutants were
characterized to elucidate the T6SS function (Figure S1). Based
on the genetic arrangement of the T6SS gene cluster, deletions of
hcp and icmF are unlikely to affect the function of downstream
genes that are not involved in T6SS (Figure 1 and Figure S1C).
A robust indicator of a functional T6SS in T6SS-harboring
bacteria is the presence of the secreted substrate, Hcp, in the
culture media [28]. To validate the secretion function of C. jejuni
T6SS and characterize the functional defect of T6SS in Dhcp and
DicmF mutants, immunoblots for Hcp were performed. In the wild
type (WT) C. jejuni, an expected 18 kD protein corresponding to C.
jejuni’s Hcp was detected in both pellet and supernatant fractions
(Figure 2). In the DicmF mutant, Hcp was present in both the pellet
and the supernatant; however, the level of Hcp in the supernatant
was substantially less than that in WT (Figure 2). In contrast, Hcp
was completely absent from both pellet and the supernatant
fractions of the Dhcp mutant. This result indicates that the anti-
Hcp antibody can detect C. jejuni Hcp with high specificity.
Furthermore, IcmF is required for the secretion of Hcp,
confirming the previously demonstrated role of IcmF in T6SS.
These results strongly suggest that C. jejuni possesses a functional
T6SS.
C. jejuni T6SS mediates growth inhibition in response to
high physiological concentrations of deoxycholic acid
(DCA)
T6SS plays crucial roles in bacterial growth, motility and
adaptation to environmental perturbations [11,14,15,16]. Dhcp1
and DicmF1 mutants of C. jejuni 43431 grew and swarmed at the
rate comparable to that of WT (Figure S2). Furthermore, no
significant difference in growth responses to NaCl, saponin and
various classes of antibiotics, including tetracycline, gentamicin,
fluoroquinolones, B-lactam (e.g., ampicillin, amoxicillin and
cephalothin), sulfonamides and vancomycin, was observed be-
tween WT and the mutants (Table 2).
As an enteric pathogen, C. jejuni must cope with the
antimicrobial effects of bile salts secreted into the intestinal tract
[29]. Growth responses of WT and the mutants in bile acids,
specifically cholic acid, deoxycholic acid (DCA) and ox bile, were
evaluated. Cholic acid, a primary bile acid generated by
hepatocytes, and DCA, a bacterial metabolite of cholic acid,
Campylobacter jejuni Type VI Secretion System
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represent two major components of the bile salt found in the
human intestine [30,31]. Ox bile contains a mixture of conjugated
and unconjugated bile acid derivatives, such as taurocholic acid,
glycocholic acid, deoxycholic acid, and cholic acid [32], allowing
simultaneous evaluation of responses to a variety of bile acid
derivatives. A significant difference in growth responses to DCA
was observed between WT and the mutants, while growth
responses to cholic acid and ox bile were similar between WT
and the mutants as shown by their similar minimum inhibitory
concentrations (MICs) of these bile salts (Table 2). During a
48 hour-period, WT and the mutants displayed the same growth
response at the range of DCA concentration of 0%–0.05% (Figure
S3A), which corresponds to the lower range of physiological
concentration of DCA found in the human large intestine [31,33].
However, at the higher range of physiological concentration of
DCA (0.075%–0.2%), found in the small intestine [33–35] and the
concentrations above this physiological range (0.3%–1%), growth
inhibition was observed in WT (Figure 3). In contrast, growth of
the mutants was maintained at the level comparable to those
grown without DCA at all concentrations tested throughout the
48 hours (Figure 3). As early as 14 hours, about a 10-fold
reduction in growth can be detected in WT relative to the
mutants at DCA concentrations of$0.075%. By 18 hours, growth
of WT was found to be significantly reduced by ,10-fold at
0.075% DCA and by 10- to 100-fold at 0.1% DCA relative to the
mutants, while no visible sign of growth could be detected in WT
at DCA concentrations of $0.2% (Figure 3). Interestingly, when
C. jejuni growth was tabulated at 36 and 48 hours, growth of WT
Figure 1. Gene organization of T6SS clusters in Campylobacter spp. Genes are plotted as arrows, starting from the beginning of the first gene
to the end of the last gene, in order of their genomic positions. Gene sizes (defined as the distance between the annotated starts and ends) are
represented by the relative length of the arrow. Arrow direction indicates the strand (i.e., forward arrows indicating genes on the positive strand and
reverse arrows indicating genes on the negative strand). For each strain, genes are plotted using the color code indicated in C. jejuni 414.
doi:10.1371/journal.pone.0042842.g001
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was observed in all concentrations tested (Figure 3). However, the
growth level of WT was restored to levels comparable to those of
the mutants at 0.75–0.2%, but not at concentrations of .0.2%
(Figure 3). This difference in growth dynamics between WT and
the mutants, in response to physiological concentrations of DCA,
was also observed in liquid culturing conditions (Figure S3B).
To further assess the differences in DCA response, the MICs of
DCA for WT and the mutants were determined. WT had an MIC
of 1.2%. In contrast, Dhcp1 and DicmF1 mutants had MICs of
.6% (Table 2). We were unable to determine the exact MICs of
the mutants due to solubility issues that were encountered when
DCA concentrations reached 6%. To determine if the DCA-
resistant phenotype observed in the mutants was the result of
T6SS deficiency, we complemented the Dhcp1 mutant in trans by
integrating the WT hcp under the control of a chloramphenicol
acetyltransferase (cat) promoter into the 16S–23S rRNA spacer
region of the Dhcp1 mutant’s chromosome (Figure S1A and S1D),
thereby creating a complemented strain, Dhcp1(hcp+), which over-
expressed hcp at levels 3 times that of WT (Figure S4). Like the
WT, the complemented strain failed to grow in media supple-
mented with 3% DCA, a concentration that exceeds the MIC of
WT (Figure 4). However, the MIC of DCA for the complemented
strain was slightly higher than that of WT (MICs: 1.5% in
Dhcp1(hcp+) versus 1.2% in WT, Table 2). The growth response to
DCA of the control Dhcp1 mutants harboring kanamycin-
resistance cassette (kat), which was also integrated into the 16S–
23S spacer region, was similar to that of the mutants suggesting
that integration of kat into the 16S–23S is not responsible for the
DCA-sensitive phenotype observed in Dhcp1(hcp+) (Figure 4B and
4D). These results indicate that a defective T6SS is responsible for
the DCA-resistant phenotype observed in the mutants. Taken
together, our data suggest that the presence of T6SS imposes a
growth constraint at DCA concentrations of $0.075%, particu-
larly during the initial exposure to DCA. Despite the initial growth
inhibition, T6SS-harboring C. jejuni is capable of restoring its
growth at the later stage, indicating that the bacteria are capable of
adapting to the upper physiological range of DCA.
Deficiency in T6SS transcriptionally down-regulates C.
jejuni multidrug transporter gene during initial exposure
to DCA
Previous studies suggest that an active secretion system may
enable unconjugated bile salts, such as DCA, to enter the bacterial
Table 1. List of T6SS orthologs of C. jejuni ATCC 43431 and their proposed functions [3,24].
T6SS
orthologue ID Gene name Proposed functions
Size (amino
acids)
NCBI protein sequence ID of C. jejuni ATCC
43431
COG3501 vrgG Membrane penetrating component, effector 869 AAS98979
COG3515 impA/vasJ Unknown function 356 AAS99033 (link to AAS99031 and AAS99032)
COG3516 impB Form tubular structure resembling tail sheath of
bacteriophages
141 Present (linked to AAS99033 and AAS99098)
COG3517 impC Form tubular structure resembling tail sheath of
bacteriophages
484 AAS99098 (link to AAS99096 and AAS99097)
COG3518 vasS Bacteriophage baseplate GP-25 like lysozyme 135 AAS99097 (link to AAS99096 and AAS99098)
COG3519 impG Unknown function 573 AAS99096 (link to AAS99097 and AAS99098)
COG3520 impH/vasB Unknown function 302 Present (linked to AAS98979, AAS99033)
COG3521 vasD Outer membrane lipoprotein involved in stabilizing
T6SS
148 AAS99032 (link to AAS99031 and AAS99033)
COG3522 impJ/vasE Unknown function 465 AAS99075 (AAS99031) (link to AAS99076)
COG3523 icmF/impL Inner membrane protein involved in T6SS
stabilization
1175 AAS98968, AAS98977
COG3455 ompA/motB/dotU/impK/
vasF
Inner membrane protein involved in T6SS
stabilization
222 AAS98993 (link to 98992)
COG3456 fha1/impL/vasC Core scaffolding protein, phosphorylated by serine-
threonine kinase
298 AAS98989
COG3157 hcp1 Membrane penetrating component, effector 171 AAS98992 (link to 98993)
doi:10.1371/journal.pone.0042842.t001
Figure 2. Western blot analysis of Hcp in WT C. jejuni, the Dhcp mutant, and the DicmF mutant. Equal numbers of WT, Dhcp and DicmF
mutants were collected (see Material and Methods). Pellet and supernatant were separated and used in immunoblot assays with an anti-Hcp
antibody. The estimated molecular weight of Hcp is 18 kD. The results are representative of three independent experiments.
doi:10.1371/journal.pone.0042842.g002
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cell through an opened secretion channel, subsequently inhibiting
bacterial growth [36]. CmeABC, which encodes C. jejuni multidrug/
bile salt efflux transporter, is positively regulated by DCA [37] and
serves as an excellent molecular marker for monitoring changes in
the intracellular DCA concentrations. We investigated whether C.
jejuni T6SS mediates intracellular influx of DCA causing cell
growth arrest by examining the expression level of cmeA, a
component of cmeABC, in WT and the Dhcp1 mutant grown in
0.1% DCA at 14 hours, a period when growth of the DCA-treated
WT was severely inhibited, while the growth of the DCA-treated
Dhcp1mutant was not (Figure 3). The transcript level of cmeA did
not differ significantly between WT and the mutants grown in
DCA-free media (Figure 5). In contrast, the transcript level of cmeA
of the DCA-treated WT was 1.5 times that of the DCA-treated
Dhcp1 mutant (p#0.01). Furthermore, the DCA-treated WT had a
cmeA level that was 4.8 times that of the untreated WT (p#0.001)
(Figure 5). In contrast, the cmeA transcript level of the DCA-treated
Dhcp1 mutant was only 1.9 times (p#0.001) that of the untreated-
Dhcp1 mutant. The DCA-treated complemented strain, which had
a DCA susceptibility comparable to that of WT, had a cmeA
transcript level that was 2.2 times (p#0.001) that of the untreated
complemented strain (Figure 5). These results support our
hypothesis that T6SS mediates intracellular influx of DCA to
inhibit C. jejuni growth.
C. jejuni cmeA and T6SS are sequentially modulated
during adaptation to deoxycholic acid
If the expression of T6SS inhibits C. jejuni growth by mediating
DCA influx, but a defective T6SS enables growth by limiting DCA
influx, down regulation of T6SS may serve as a mechanism for
ensuring survival of T6SS-harboring C. jejuni in DCA. We next
investigated the relationship between T6SS and the bile efflux
transporter by characterizing temporal expression patterns of hcp,
icmF and cmeA in WT during growth in biphasic culture media free
of or supplemented with 0.1% DCA. We targeted three time
points—12 hours when growth of the DCA-treated WT was
inhibited; 24 hours; and 48 hours when growth was restored
(Figure 3). In DCA-free media, hcp and icmF were transcribed
throughout the entire growth phase. hcp was expressed at a steady
level throughout the entire 48 hours, whereas transcript levels of
icmF showed an increasing trend from 12 to 48 hours (Figure 6A).
Compared to hcp, the transcript level of icmF was significantly
lower at all time-points (Figure 6A and 6B). No significant
difference in hcp and icmF transcript levels was observed between
the DCA-treated WT and the untreated controls at 12 hours
(Figure 6A and 6B). However, the hcp transcript level of the DCA-
treated WT was significantly less than that of the untreated control
at 24 (p#0.05) and 48 hours (p#0.01, Figure 6A). Likewise, the
icmF transcript level of the DCA-treated WT was significantly
decreased compared to that of the untreated control at 48 hours
(p#0.001, Figure 6B). In contrast, the DCA-treated WT had a
cmeA transcript level that was 2 times that of the untreated WT at
12 hours (p#0.001) (Figure 6C). However, no significant differ-
ence in the transcript levels of cmeA was detected between the
DCA-treated and the untreated WT at 24 and 48 hours
(Figure 6C). The above results demonstrate that T6SS is down-
regulated when C. jejuni growth is restored, supporting the view
that down-regulation of T6SS function enables C. jejuni to survive
in DCA. The observed initial up-regulation of cmeA further
substantiates the notion that T6SS mediates DCA influx.
Considering the roles of cmeA in bile resistance, these results
indicate that the coordinated transcriptional regulation of the bile
efflux transporter and T6SS may represent, in part, an adaptive
mechanism for ensuring C. jejuni survival in high physiological
concentrations of DCA.
C. jejuni T6SS is required for adherence to and invasion of
in vitro T84 human colonic epithelial and murine RAW
264.7 macrophage cell lines
Recent studies in E. coli suggest that T6SS promotes host cell
adhesion and invasion, the two fundamental processes required for
host colonization and the attainment of full virulence [23,38]. To
Table 2. Responses of WT C. jejuni ATCC 43431, Dhcp and DicmF mutants, and the complemented Dhcp1 (hcp1(hcp+)) to bile salts,
NaCl, saponin, different pH and antibiotics.
Agents/antibiotics WT Dhcp1(hcp+) Dhcp1 Dhcp2 DicmF1 DicmF2
Cholic acid (MIC, mg/ml) 40,000 40,000 40,000 40,000 40,000 40,000
Deoxycholic acid (MIC, mg/ml) 12,000 15,000 .60,000 .60,000 .60,000 .60,000
Ox bile (MIC, mg/ml) 50,000 50,000 50,000 50,000 50,000 50,000
Ampicillin S(29) S(29) S(29) S(29) S(29) S(29)
Amoxycillin/clavulonic acid S(38) S(38) S(38) S(38) S(38) S(38)
Cephalothin R(0) R(0) R(0) R(0) R(0) R(0)
Gentamicin S(29) S(29) S(29) S(29) S(29) S(29)
Tetracycline S(32) S(32) S(32) S(32) S(32) S(32)
Enrofloxacin S(38) S(38) S(38) S(38) S(38) S(38)
Trimethoprim/sulfomethazole S(24) S(24) S(24) S(24) S(24) S(24)
Nalidixic acid S(31) S(31) S(31) S(31) S(31) S(31)
Vancomycin R(0) R(0) R(0) R(0) R(0) R(0)
NaCl (MIC, mg/ml) 10,000 10,000 10,000 10,000 10,000 10,000
Saponin (MIC, mg/ml) 15,000 15,000 15,000 15,000 15,000 15,000
pH (non-lethal range) 5–9 5–9 5–9 5–9 5–9 5–9
( ): approximate diameter of zone of growth inhibition in millimeter. Sensitivity (S) versus resistance (R) to antibiotics was determined based on the zone diameter value
for Enterobacteriaceae reported by the manufacturer (BD, BBL). Experiments were performed on three independent occasions.
doi:10.1371/journal.pone.0042842.t002
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explore the roles of C. jejuni’s T6SS in these processes, we
evaluated the cell adhesion and internalization potentials of Dhcp1
and DicmF1 mutants and WT in in vitro T84 colonic epithelial and
RAW 264.7 macrophage cell lines. Compared to the parental
WT, the mutants showed a significant reduction, by approxi-
mately 50% of that observed in WT, in their abilities to adhere to
and invade the T84 cell line (Figure 7A and 7B). Likewise, the
RAW 264.7 adherence and invasion efficacy/number of bacteria
phagocytized by RAW 264.7 of the mutants was approximately
50% lower than that of WT (Figure 7C and 7D). Remarkably, the
complemented strain, which over-expressed hcp, adhered to and
invaded the T84 and RAW 264.7 at levels of approximately 4
times and 2 to 3 times that of WT, respectively (Figure 7A and 7B).
The control Dhcp1 mutants harboring kat exhibited cell adhesion
and invasion characteristics similar to the mutants (Figure 7). The
higher rates of cell adhesion and invasion exhibited by the
complemented strain were likely due to the overexpression of hcp,
but not the higher rate of cell proliferation and motility as the
complemented strain grew and swarmed at the rate comparable to
WT and the mutants (Figure S2). These results indicate that the
reduced efficacy of cell adhesion and invasion observed in the Dhcp
mutant resulted from hcp deficiency. Collectively, these data
Figure 3. Growth dynamics of WT C. jejuni, the Dhcp1 mutant, and the DicmF1 mutant in various sub-inhibitory concentrations of
DCA. Ten-fold serial dilutions of WT and the mutants were spotted on agar plates lacking or supplemented with DCA at concentrations ranging from
0% to 1%. Growth was inspected at 14, 18, 36 and 48 hours after incubation under microaerobic conditions. The results are representative of three
independent experiments.
doi:10.1371/journal.pone.0042842.g003
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suggest that C. jejuni T6SS promotes host cell adhesion and
invasion and that hcp-mediated cell adhesion and invasion operate
in a dose-dependent fashion.
C. jejuni T6SS is required for persistent colonization in IL-
10-deficient mice
Although the above findings suggest that T6SS defects may not
affect C. jejuni’s ability to multiply and survive when exposed to
DCA in the small intestine, the defects are likely to prevent C. jejuni
from adhering to and invading the epithelial lining of the colon. As
host cell adhesion and invasion are crucial for enteric pathogens to
colonize and exert their pathogenic potential and/or establish
persistence, we hypothesized that T6SS defects would adversely
affect C. jejuni in vivo colonization potential. We compared the
colonization potential of WT and T6SS-deficient strains in the
B6.129P2-IL-10tm1Cgn mice, proven to be a useful model for
evaluating C. jejuni colonization of the large intestine [39,40]. C.
jejuni 43431 and 2 independent C. jejuni DicmFmutants (DicmF1 and
DicmF2) were used to experimentally inoculate 6 to 7 week-old
male and female IL-10-deficient mice (see Material and
Methods). At 30 days post inoculation (p.i.), mice were
euthanized and their cecal tissues and fecal samples were
quantitatively analyzed for C. jejuni by q-PCR. C. jejuni was not
detected in either the cecal tissues or the feces of 10/10 sham-
dosed control mice (Figure 8A and 8B); however, WT C. jejuni was
detected in the cecal tissues of 7/10 mice at the mean copy
number of C. jejuni/mg of host DNA of 1066967120 (mean6-
standard error). In contrast, the C. jejuni DicmF1 mutant was
detected in only 3/10 mice at 8776867copy numbers/mg and in
1/10 mice inoculated with the C. jejuni DicmF2 mutant at 1.761.7
copy numbers/mg (Figure 8A). This was consistent with the results
obtained from the fecal samples (Figure 8B): WT: 156522670250
copy numbers/mg (7/10 mice) versus DicmF1: 340562189 copy
numbers/mg (3/10 mice) and DicmF2: 0 copy number/mg (10/10
mice). The finding that numbers of C. jejuni were significantly
reduced in mice infected with DicmF mutants compared to those
infected with WT indicates that T6SS is instrumental in C. jejuni to
establish a persistent colonization.
Discussion
In our studies, we demonstrated that the human clinical isolate,
C. jejuni ATCC 43431, possesses a T6SS gene cluster that encodes
a functional secretion system. To our knowledge, this is the first
report of a functional characterization of T6SS in Campylobacter
jejuni. Importantly, our study reveals the role of T6SS in host cell
adhesion, invasion, and a novel role of T6SS in adaptation to a
specific bile salt, deoxycholic acid, which together contribute to the
ability of this strain of C. jejuni to establish in vivo colonization.
Unlike other known T6SSs, the T6SS of C. jejuni and
Campylobacter spp. appears to lack ClpV belonging to AAA+ family
of ATPases, which was hypothesized to provide the energy toT6SS
and is present in most T6SS-harboring bacteria [41]. This lack of
ClpV in the T6SS of C. jejuni is shared with Francisella tularensis, H.
hepaticus, S. cholerasuis, and Burkholderia spp. [8,42]. Further analyses
are required to determine how the lack of ClpV is compensated for
in C. jejuni and the aforementioned species. The variation in the
arrangement of T6SS genes within T6SS clusters of different
Campylobacter spp. may contribute to adaptation to specific hosts or
niches. Intriguingly, the T6SS of C. jejuni 43431 is the exact replica
of C. coli RM2228, but is distinct from those of C. jejuni 414 and C.
jejuni BH-01-0142. Furthermore, 3 of the 14 (21%) strains of C.
jejuni analyzed in this study harbor T6SS gene clusters, while the
rest of the C. jejuni strains, including the well characterized human
clinical isolates, C. jejuni 81–176, C. jejuni 81116 and C. jejuni 11168,
do not contain T6SS. Interestingly, both T6SS-positive strains, C.
jejuni 43431 and C. jejuni BH-01-0142, belong to the same
serodeterminant capsule of the HS3 serogroup, whereas the
T6SS-negative strains, such as C. jejuni 81–176, belong to a distinct
serogroup, HS23,36 [27]. Additional studies are required to
determine whether T6SS is conserved among strains within the
Figure 4. Growth responses of WT C. jejuni, Dhcp and DicmF
mutants, and the complemented Dhcp1 strain, Dhcp1(hcp+), on
agar free of or supplemented with 3% DCA. (A) WT, Dhcp and
DicmF mutants harboring cat (hcp1, hcp2, icmF1, icmF2), complemented
Dhcp1 strain, Dhcp1(hcp+), and the control Dhcp1 mutant harboring kat
(Dhcp1(kat)) grown on a DCA-free agar and (B) supplemented with 3%
DCA. (C) WT, Dhcp and DicmF mutants harboring kat (hcp3, hcp4, icmF3,
icmF4), Dhcp1(hcp+) and Dhcp1(kat) grown on a DCA-free agar and (D)
supplemented with 3% DCA.
doi:10.1371/journal.pone.0042842.g004
Figure 5. Expression levels of cmeA in WT C. jejuni, the Dhcp1
mutant, and the complemented Dhcp1 strain, Dhcp1(hcp+),
grown in liquid media free of or supplemented with 0.1% DCA
after 14 hours of growth. The Y axis represents the ratio of cmeA
copy number and the copy number of a house keeping gene, glyA,
previously shown to not be affected by DCA [55]. The graph represents
results from two independent experiments. Error bars represent the
standard error of the mean. P value: **#0.01, ***#0.001.
doi:10.1371/journal.pone.0042842.g005
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HS3 serogroup and how T6SS may contribute to their patho-
genesis.
The in vivo survivability of enteric pathogens depends on their
ability to colonize and interact with their target host [42]. Our
results suggest that C. jejuni T6SS is involved in these processes
with Hcp acting as a key mediator. Hcp-mediated cell adhesion
and invasion appears to operate in a dose-dependent fashion.
Over-expression of hcp in the complemented strain further
enhanced cell adhesion and invasion compared to WT and, to a
greater extent, the mutants. In the meningitis-causing E. coli K1
strain RS218, the secreted Hcp1 and the non-secreted Hcp2
encoded by its T6SS gene cluster promote invasion and adhesion,
respectively, to human brain microvascular endothelial cells
(HBMEC) [23]. Since it was not secreted, it was proposed that
Hcp2 acts as a structural protein facilitating HBMEC adhesion by
interacting with the host cell surface protein. In contrast, the
secreted Hcp1 serves as an effector protein, which upon entering
the host intracellular compartment, induces actin cytoskeletal
rearrangement, cytokine production, and apoptosis. Unlike E. coli,
C. jejuni 43431 contains only a single secreted Hcp that promotes
both host cell adhesion and invasion. C. jejuni Hcp may, therefore,
serve as both a structural protein that facilitates host cell adhesion
and as an effector that promotes host cell invasion.
T6SS has been implicated in bacterial growth, motility, and
survival under different stress conditions. Although C. jejuni T6SS
components are constitutively expressed during growth under
normal in vitro growth conditions, the T6SS is not essential for
viability, growth, or motility. However, a functional T6SS
increases susceptibility of C. jejuni to a bile salt, DCA. Alterations
in the outer membrane permeability barrier can lead to increased
permeability to DCA [43]. However, the WT’s and the mutants’
growth responses to hydrophobic (e.g. trimethoprim) and hydro-
philic (e.g. ampicillin and tetracycline) antibiotics were similar,
implying that T6SS has no impact on the integrity of the
membrane permeability barrier. Thus, this mechanism is unlikely
to contribute to the DCA-sensitive phenotype. The possible
Figure 6. Temporal expression patterns of hcp, icmF, and cmeA during growth of C. jejuni in biphasic culture media free of or
supplemented with 0.1% DCA. The transcript levels of (A) hcp, (B) icmF, and (C) cmeA of WT C. jejuni grown in the presence or absence of 0.1%
DCA at 12, 24 and 48 hours of growth. The Y axis represents the ratio of hcp, icmF or cmeA copy number and the copy number of a house keeping
gene, glyA. The graphs represent results from at least three independent experiments. Error bars represent the standard error of the mean. P value:
*#0.05, **#0.01, ***#0.001.
doi:10.1371/journal.pone.0042842.g006
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mechanism of T6SS-mediated DCA sensitivity is an increase of
intracellular influx of DCA. This is based on the finding that cmeA,
a bile efflux transporter gene previously shown to be positively
regulated by DCA, was significantly up-regulated in the DCA-
treated WT relative to both the untreated control and the T6SS-
deficient strains during the initial exposure to DCA when C. jejuni
growth was inhibited. The type IV secretion system (T4SS) of E.
coli was implicated in mediating bile acid sensitivity, specifically to
unconjugated bile acids, such as DCA and cholic acid, as well as
sodium dodecyl sulfate [36]. It was proposed that T4SS and
possibly other types of secretion systems, when transiently
activated, allow macromolecules of a suitable size and chemistry,
such as unconjugated bile acids, to passively enter the cells and
inhibit cell growth. It remains to be determined whether a similar
mechanism for C. jejuni T6SS exists.
Despite the severe growth inhibition at the extreme DCA
concentrations, C. jejuni expressing T6SS is able to adapt to the
inhibitory effect of physiological concentrations of DCA. Our
results suggest that this is in part due to the sequential modulation
of the bile efflux transporter and the T6SS activity, which is
characterized by the initial up-regulation of cmeA and the
subsequent down-regulation of hcp and icmF. It is likely that the
initial increase in the bile efflux transporter activity enables C. jejuni
to counteract the DCA influx mediated by T6SS, while the
subsequent down-regulation of T6SS activity allows C. jejuni to
survive by limiting DCA influx. Thus, the coordinated regulation
Figure 7. Adhesion and invasion efficacy of WT C. jejuni, the Dhcp1mutant, the DicmF1mutant, and the complemented Dhcp1 strain,
Dhcp1(hcp+), in human T84 colonic epithelial and RAW 267.4 macrophage cell lines. (A) T84 adhesion efficacy, B) T84 invasion efficacy, (C)
RAW 267.4 macrophage adhesion efficacy and (D) RAW 267.4 macrophage invasion efficacy. The graph represents results from three independent
experiments. Error bars represent the standard error of the mean. P value: *#0.05, **#0.01, ***#0.001.
doi:10.1371/journal.pone.0042842.g007
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of the bile efflux transporter and the T6SS may represent an
adaptive mechanism for ensuring C. jejuni survival during exposure
to the upper range of physiological concentrations of DCA.
Our in vitro analyses suggest that Hcp plays a pivotal role in
promoting host cell adhesion and invasion since the over-
expression of hcp enhanced cell adherence and invasion in the
complemented Dhcp1 strain. However, the complemented strain
displayed a greater resistance to DCA as well as a lower cmeA level
during the initial exposure to DCA compared to WT. This is most
likely the result of altered stoichiometry caused by the constitutive
and/or over-expression of a secreted component of T6SS in trans
[44].
The human intestinal tract is characterized by a gradient of
DCA concentration with the highest concentration found in the
duodenum and the lowest in the distal colon. The intra-duodenal
concentration of total bile salt can range from 6.9 (,0.3%)–9.3
(,0.4%) mM [35] and is gradually decreased to 2 mM (,0.1%) in
the lower ileum [34]. Relative to the small intestine, the total bile
salt concentration is low in the cecum and was reported to be in
the range of 0.14 mM (0.006%)–0.93 (0.04%) mM [31]. Of the
Figure 8. Colonization potential of WT C. jejuni, the DicmF1 mutant, and the DicmF2 mutant in IL-10-deficient mice at 30 days post-
infection. The number of WT C. jejuni 43431 and the mutants in the cecum (A) and the feces (B) of individual mice were quantified by Q-PCR (see
Material and Methods) and the values plotted. A solid line represents the mean value for each group. P value: *#0.05, **#0.01, ***#0.001.
doi:10.1371/journal.pone.0042842.g008
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total bile acid, the concentration of DCA can vary from 0% to
more than 50% depending on the individual [33]. Based on the
current understanding of this DCA concentration gradient, we
proposed a model explaining how temporal and spatial regulation
of T6SS in response to the gradient of DCA dictates T6SS-
harboring C. jejuni’s colonization dynamics and pathogenic
potential in the human gastrointestinal tract. After C. jejuni survives
the acidic environment of the stomach and enters the small
intestine, T6SS, which is constitutively expressed in the absence of
DCA, allows DCA to enter C. jejuni resulting in cell growth arrest.
The increase in the intracellular concentration of DCA first up-
regulates cmeA and then down-regulates T6SS expression.
Ultimately, these two convergent processes synergize to promote
a reduction of intracellular DCA, thereby restoring homeostasis
and C. jejuni growth. Although C. jejuni is able to grow and multiply
in the small intestine, the relatively low level of hcp and icmF
attenuates the ability of C. jejuni to adhere to and invade the small
intestine. Thus, the T6SS-harboring C. jejuni would not be able to
effectively colonize this region of the intestine. However, as C. jejuni
reaches the proximal colon, where the concentration of DCA is
non-inhibitory (,0.05%), the restriction on T6SS expression is
released, enhancing the capability of C. jejuni to adhere to and
invade the mucosal epithelia and macrophages. Consequently, C.
jejuni containing T6SS can establish colonization and induce
colonic inflammation.
Our proposed model of colonization dynamics is consistent with
the clinicopathologic features reported in humans in which
pancolitis was the most common and consistent pathologic
characteristic [45–47]. Interestingly, some studies reported two
distinct patterns of pathology – lesions confined to the large
intestine and those distributed in both the small and the large
intestine [48]. Given the great genetic variability among C. jejuni
strains, it is reasonable to assume that certain strains of C. jejuni
have evolved to colonize and invade both the small and large
intestine, while other strains, such as T6SS-harboring strains, have
evolved to effectively colonize the colon. Indeed, mice inoculated
with C. jejuni 43431 showed higher levels of persistent colonization
in the large intestine compared to those inoculated with the T6SS-
defective mutants.
In summary, our in vitro analyses revealed that T6SS isogenic
mutants displayed approximately a 50% reduction in cell adhesion
and invasion compared to WT C. jejuni. There results were
complemented by the in vivo studies demonstrating the importance
of T6SS in establishing persistence colonization. Further, this
study demonstrates the role of T6SS in mediating DCA sensitivity
and suggests the functional plasticity of the T6SS –the regulation
of bile acid adaptation and host colonization – providing novel
insights into the roles of T6SS in C. jejuni pathogenicity.
Materials and Methods
Bacterial strains and culturing methods
Campylobacter jejuni subsp. jejuni serotype O:3 (ATCCH43431TM,
Manassas, VA) was propagated on blood agar containing 5%
defibrinated sheep blood (Remel, Lexington, KS) or in biphasic
growth media [49] containing an equal volume of Brucella agar
and Brucella broth (BD, Franklin Lakes, NJ). When appropriate,
the media were supplemented with chloramphenicol (Cm,
25 mg ml21) and/or kanamycin (Kn, 50 ug ml21). Bacterial
culture were incubated in GasPak jar filled with microaerobic
gas mixtures (10% H2, 10% CO2, 80% N2) in a humidified 37uC
incubator as previously described [50].
Molecular techniques
Bacterial genomic and plasmid DNA were isolated using a
Roche High Pure PCR Template Preparation kit (Roche Applied
Science, Indianapolis, IN) and QIAprep Spin Miniprep Kit
(Qiagen, Valencia, CA), respectively, according to the manufac-
turer’s recommendations. The sequences of T6SS orthologs of C.
jejuni ATCC 43431 were obtained by PCR with primers listed in
Table 3. PCR amplification using Expand High Fidelity PCR
system (Roche Applied Science) was performed with Gene Amp
PCR system 9700 (AB Applied Biosystems, Carlsbad, CA). DNA
sequencing was accomplished using the ABI prism Genetic
Analyzer 3500 (Invitrogen, Carlsbad, CA). E. coli strains Top10
was used as a recipient for cloning, mutagenesis, and plasmid
propagation. E. coli was cultured in Luria-Bertani (LB) agar or
broth (BD) with continuous shaking (250 rpm) at 37uC under
aerobic conditions. When appropriate, the plates were supple-
mented with ampicillin (50 mg ml21), Cm and/or Kn as
mentioned above.
Anti-Hcp antibody production
Custom anti-Hcp antibody was produced against the most
antigenic epitope (CSGQPSGQRVHKPFSF) that is highly
conserved among T6SS-positive Helicobacter spp. and Campylobacter
spp. by Covance Inc. (Denver, PA) from the initial stage of Hcp
peptide production to affinity purification of the antibody. Two
New Zealand white rabbits were used in the standard 77-day
protocol that was approved by the MIT Animal Care Committee.
Bleeds were checked against purified Hcp peptide by ELISA and
Western blot analysis. Antibody was enriched by affinity purifi-
cation and was used for the subsequent analyses.
Hcp secretion assay and Western Blot analysis
The Hcp secretion assay was performed according to a
previously published protocol [10]. Briefly, equal numbers of
WT C. jejuni 43431 and Dhcp1 and DicmF1 mutant cells were
harvested from liquid cultures at the logarithmic growth phase
based on OD600 nm readings and the supernatant was separated
from the cells by centrifugation and passed through a 0.2 mm
syringe filter (Millipore, Billerica, MA). Hcp was detected by
incubating with the custom anti-Hcp primary antibody (Covance,
as described previously, 1:1000 dilution) for 1 hour at room
temperature, followed by incubation with an HRP-conjugated
goat anti-rabbit IgG secondary antibody (1:10,000 dilution;
Zymed, CA) for 1 hour at room temperature. Protein was
transferred to a 0.2 mm PVDF membrane (Biorad, Hercules,
CA) with a Trans-Blot Turbo transfer system (Biorad). Antibody
binding was visualized with a Lumigen PS-3 chemiluminescent
HRP detection kit (Lumigen, Southfield, MI) according to the
manufacturer’s recommendations.
Generation of Dhcp and DicmF mutants
Four Dhcp mutants (2 mutants with cat oriented in opposite
orientation, Dhcp1 and Dhcp2, and 2 mutants with kat oriented in
opposite orientation, Dhcp3 and Dhcp4) and 4 DicmF mutants
(DicmF1, DicmF2, DicmF3, and DicmF4) were generated by allelic
replacement via homologous recombination (Figure S1). To create
plasmid constructs used to generate Dhcp mutants, the 247-bp
DNA fragment in the upstream 59 region of the gene was
amplified by PCR using the forward primer (hcp59BAMHIF) and
reverse primer (hcp39HINCIIR). The 353-bp region located at the
distal portion of 39 region was amplified using the forward primer
(hcp59HINCIIF) and reverse primer (hcp39XHOIR) (Table 3). The
two PCR products were ligated into the BamHI and XhoI sites of
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the suicide vector pBluescript-II SK and the resulting plasmid was
circularized at the HincII sites of the two PCR products. cat
(750 bp) of C. coli and kat (1300 bp) were excised from pBluescript-
II SK vector with HincII and ligated into the HincII sites of the
constructs effectively deleting a large middle portion of the hcp
gene. Restriction endonucleases were obtained from New England
Biolab (Ipswich, MA). The ligation reactions were performed using
T4 DNA ligase (New England Biolab) according to the manufac-
turer’s recommendations. The constructs used to create the DicmF
mutants were generated in similar fashion as described for Dhcp
mutants with icmF-specific primers (Table 3). The orientation of cat
and kat was determined by restriction enzyme analyses and was
subsequently confirmed by DNA sequencing.
Bacterial transformation was performed by electroporation as
previously described with minor modifications [51]. All mutants
were passaged five times to ensure the elimination of any WT
contaminants. Authenticity of the mutants was verified by PCR
(Figure S1A and S1B) using gene-specific primers listed in Table 3.
Complementation of Dhcp1 mutants
The Dhcp1 mutant was complemented in trans by stably
integrating WT hcp coding sequence under the control of the cat
promoter into the 16S–23S rRNA intergenic spacer region of the
Dhcp1 mutant chromosome by the method previously described
[52]. The complementation construct was generated by PCR
amplification of 59 and 39 regions of 16S–23S using primers listed
in Table 3. The 16S–23S sequences were cloned into the suicide
vector mentioned above. A cat promoter sequence was amplified
from the aforementioned vector and cloned into the middle of the
16S–23S sequences. hcp and kat coding sequences engineered to
contain ribosome binding sites were amplified with primers listed
in Table 3 and cloned into the vector immediately downstream of
the cat promoter effectively generating a hcp/kat operon. The
construct was transformed into E. coli Top10 and positive clones
were selected based on resistance to Kn. The construct was
sequenced to ensure sequence correctness and was transformed
into the Dhcp1 mutant by electroporation as previously mentioned.
The complemented Dhcp1 strain (Dhcp1(hcp+)) was selected based
on the resistance to Kn and Cm and confirmed by PCR and DNA
sequencing (Figure S1A).
In silico analysis
We analyzed the proteome sets of the following, including C.
jejuni strains and clinically relevant Campylobacter spp.: C. jejuni-81-
176, C. jejuni-CG8421, C. jejuni-BH-01-0142, C. Coli-RM2228, C.
concisus 13826, C. rectus, C. jejuni-S3, C. jejuni-RM1221, C. jejuni-M1,
C. jejuni-ICDCCJ07001, C. jejuni-IA3902, C. jejuni Doylei-269, C.
jejuni-1336, C. jejuni-81116, C. jejuni-43431, C. jejuni-NCTC-11168
and C. jejuni 414. For each, the respective available proteome set
was downloaded from the EBI or the NCBI. One proteome set,
i.e., that of C jejuni 43431, had to be retrieved from the genome
sequencing contigs from NCBI, as there was no full proteome set
available for downloading from either EBI or NCBI.
The proteome sets were then BLASTed against NCBI’s
Reference Sequence Project Protein database using blastp with
default parameters. BLAST results were saved as XML files. Each
BLAST XML file for the respective proteome set was used to filter
for proteins homologous to known T6SS-related proteins (e.g.,
icmF, hcp, vrg, imp, vas) using a Perl script we wrote, which utilizes
BioPerl’s Bio::SearchIO module.
Growth and motility assay
For the motility assay, overnight C. jejuni cultures were
harvested, suspended in 16PBS and diluted to OD600 nm of 0.1.
Two ml of the sample (,105 CFUs) was spotted in the center of
semisolid motility agar plates containing Brucella broth and 0.3%
(w/v) agar adjusted to pH of 7. The plates were cultured for
24 hours and inspected for halos formed on semisolid agar as an
indicator of motility. For growth assays, overnight C. jejuni cultures
were added to the biphasic growth media to achieve OD600 nm of
0.1. The cultures were incubated under microaerobic conditions
Table 3. Primers used in this study.
Primer name Primer sequences
Primers for confirmation of T6SS genes
icmF1 59-TATAGGATCCGTGTTCTTCTAAATTTGAAAATGT-39
icmF2 59-TATACAGCTGTTATCGTACCTCTCCTTGGCGAT-39
icmF3 59-TATAGGATCCGAATTTAGAAAATTTTAATGTTGGCA-39
icmF4 59-TATACAGCTGTTAAAATTTTCTAAAATTTACTGGAA-39
hcp1 59-TATAGGATCCGACTCCTACTGGAGATTTGAAAGATT-39
hcp2 59-TATACAGCTGTTATTCTAAAGGGGTAGCAGCTGTT-39
COG3515-F 59-AAGGGAGAATGACTCATAGCCGCA-39
COG3516-F 59-ATGTCAGATGGATCTTATGCTC-39
COG3516-R 59-TTAATTTCCTTGCTCTTCTTG-39
COG3517-R 59-GCTCAAGTTGCACCACAACTTCCA-3
COG3456-R 59-TCAATGCTTTTTGCATCCAC-39
COG3501-F 59-TCCTTACCTTAACCCTTCCATGCTC-39
COG3520-F 59CATCGTGTTTGGTTCCATTGGGCA-39
COG3520-R 59-ATGAATAATCTTACTTCATATAGT-39
Primers for Q-PCR
hcpRTPCR-F 59-TGCCAAATGCGCAAGAGTCAAGT-39
hcpRTPCR-R 59-TTCCGCTAGTTCCAGCAGCAGTAT-39
icmFRTPCR-F 59-TCTGACATCGAATACCCACTTAGTGA-39
icmFRTPCR-R 59-GTATTTCATCGCTACTTGTAGGCTTA-39
cdtARTPCR-F 59-AATGCATACAAGCACCTATTACAA-39
cdtARTPCR-R 59-TATACTGCAGTTATCGTACCTCTCCTTGGCGATATA-39
Primers for generation of Dhcp and DicmF mutants
hcp59BAMHI-F 59-TATAGGATCCTACTGAAGCGAGTATTGGCAA-39
hcp39HINCII-R 59-TATAGTCGACTTGTTGCGGTTCTAAACCA-39
hcp59HINCII-F 59-TATAGTCGACTTATAATTTATCTTAAATAATCCT-39
hcp39XHOI-R 59-TATACTCGAGTATTAAGCTATGCAAT-39
icmF59BAMHI-F 59-TATAGGATCCATCAAGATTATTTATAACTGCTT-39
icmF39HINCII-R 59-TATAGTCGACTGTAAATGAACTCATCAGCTT-39
icmF59HINCII-F 59-TATAGTCGACATCACCAATGCAGGCAATCT-39
icmF39XHOI-R 59-TATACTCGAGTTATTTAATTCACTAGCACCGTT-39
Primers for generation of the complemented Dhcp1 strain
16S-23SBAMHI-F 59-TATAGGATCCACGCAATACCGCGAGGT-39
16S-23SNOTI-R 59-TATAGCGGCCGCTGCATAATGCTATATGCTACT-39
pCATBAMHI-F 59-TATAGGTACCTCTAGAGTGATATAGATTGAAAAGTGG-39
pCATECORI-R 59-TATAGAATTCGTCGACGTAAATTCCGATTTGTTGAT-39
cjhcpHINCII-F 59TATAGTCGACTTAAGAAGGAGATATACATATGGCTGAA-
CCAGCGTT-39
cjhcpXHOI-R 59-TATACTCGAGTTAAGCTTTGCCCTCTCTCCA-39
katECORIXHOI-F 59TATAGAATTCTCGAGAAGGAGATATACATATGATTGAAC-
AAGATGGAT-39
KatXBAI-R 59-TATATCTAGATCAGAAGAACTCGTCAAGAA-39
doi:10.1371/journal.pone.0042842.t003
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with continuous shaking (100 rpm) and OD600 nm was measured
at various time points. Three independent experiments were
performed for growth and motility assays. Gram’s staining was
conducted to determine the purity of each sample. PCR with hcp-
and icmF-specific primers were used to confirm the identity of WT,
the mutants, and the complemented strains at the beginning and
the end of the growth assays.
Bile acids, salt (osmolarity), saponin and pH assays
Two ml (,105 CFUs) of overnight culture of WT and the
mutants was spotted and grown on Brucella agar plates
containing 1.5% agar adjusted to a pH ranging from 4–10
or on Brucella agar plates adjusted to pH of 7 supplemented
with cholic acid (0%–5% (50 mg ml21) w/v); Sigma Aldrich,
St. Louis, MO), ox bile (0%–5%; Sigma), sodium deoxycholate
(0%–6%; DCA; Sigma), NaCl (0%–5%; Sigma) and saponin
(0%–3%; Sigma). The desired pH of the solution was achieved
with 1 M HCl and 1 M NaOH. MICs of each factor tested
were determined by identifying concentrations that completely
inhibited C. jejuni growth after 48 hours of incubation. To
evaluate the growth dynamic of WT and the mutants in the
presence and the absence of DCA, fresh bacterial samples were
adjusted to OD600 nm of 0.1 and were subjected to 10-fold
serial dilutions. Two ml dilution of each dilution was spotted on
Brucella agar plate supplemented or not supplemented with
0.1%DCA and incubated for specified times before recording
observations. To evaluate the growth dynamics of WT and the
mutants in different DCA concentrations under liquid culturing
condition, overnight bacterial cultures were seeded in 5 ml
Brucella broth to achieve an OD600 nm of 0.1 and incubated
under microaerobic conditions until specified time points. The
number of viable bacteria that were present in each sample
and time point was determined by 10-fold serial dilutions,
plating, and enumeration of CFUs. All experiments were
conducted on three independent occasions.
Antimicrobial assays
To evaluate the response to antibiotics, semiquantitative in vitro
susceptibility testing by the agar disk diffusion method was
performed according to the manufacturer’s recommendations
(BBL, Becton, Dickinson and Company, Sparks, MD). The disc
content was as followed: tetracycline (30 mg) and vancomycin
(30 mg) (BD BBL, Franklin Lakes, NJ) and ampicillin (10 mg),
trimethoprim (1.25 mg)/sulfamethoxazole (23.75 mg), gentamicin
(120 mg), amoxicillin (20 mg)/clavulonic acid (10 mg), nalidixic
acid (30 mg), cephalothin (30 mg) and enrofloxacin (5 mg) (Remel,
Lenexa, KS). After 48 hours of incubation under microaerobic
conditions, the sensitivity to each drug was quantified by
measuring the zone of growth inhibition in millimeters. Because
no standardized interpretive criteria exist for Campylobacter spp.,
the inhibition zone diameters were interpreted based on the
interpretative criteria for the family Enterobacteriaceae [53]. Three
independent experiments were performed in duplicates.
In vitro cell line culture procedures
A stock culture of T84 (a human colonic epithelial cell line;
ATCC, CCL 6) was maintained in 1:1 mixture of Han’s F12 and
Dulbecco’s modified Eagles medium (DMEM:F12; ATCC)
supplemented with 5% (vol/vol) fetal bovine serum, penicillin
(100 U ml21) and streptomycin (100 mg ml21) according to
ATCC’s recommendation. RAW 264.7 murine macrophages
(ATCC) were propagated in DMEM (ATCC) supplemented with
5% FCS (ATCC). The cell line cultures were maintained in 37uC
humidified incubator aerated with 5% CO2. Culture media was
replaced biweekly with new growth media to maintain the cell line.
Cell adhesion and invasion (gentamicin-protection)
assays in T84 and RAW 267.4 cells
C. jejuni was propagated on blood agar for 16 hours under
microaerobic conditions before bacteria were collected and used in
the experiment. Viable organisms were predominantly spirally
shaped and no contamination by other types of bacteria was noted
as visualized by Gram’s staining. Cell adhesion and gentamicin-
protection assays were performed according to the published
protocol with some modifications [54]. Briefly, approximately
86105 of T84 and 26105 RAW 267.4 cells were initially seeded
per well in a 12–well and 24-well tissue culture plate, respectively.
T84 and RAW 267.4 were infected with C. jejuni with the MOI of
15 and MOI of 9, respectively. The cell monolayer was incubated
with bacteria for 4 hours and was washed five times with 16PBS
to remove bacteria that failed to bind to the cells. The cell
monolayer was treated with 1% saponin (Sigma) for 15 min and
vortexed for 1 minute to release the bacteria. Enumeration of total
adhered bacteria was performed by 10-fold serial dilution and
plating.
Gentamicin-protection assays were performed according to the
cell adhesion assay described above. However, after 4 hours of
incubation, the culture was rinsed 3 times with 16 PBS and
incubated for additional 2 hours in culture medium containing
gentamicin (250 mg ml21). C. jejuni was not recovered from the
supernatant with this concentration of gentamicin and duration of
treatment. The released intracellular bacteria were enumerated by
serial dilutions and plating. Three independent assays were
performed in triplicates or quadruplicates.
Gene expression analysis
Total RNA was obtained from C. jejuni using a combination of
Trizol and RNeasy Mini kit (Qiagen) according to the manufac-
turer’s recommendations. For temporal gene expression analysis,
bacteria were grown in biphasic growth medium with or without
0.1% DCA supplementation under microaerobic conditions. After
12, 24 and 48 hours, bacterial samples were collected by
centrifugation and immediately suspended in 1 ml of Trizol
(Invitrogen). The RNA was subjected to DNase treatment using
the RNase-Free DNase set (Qiagen), purified with RNeasy Mini
Kit, and quantified using Nanodrop 2000C spectrophotometer
(Thermo Fischer Scientific, Barrington, IL). cDNA synthesis was
performed using 200 ng of total RNA, 500 nM of each reverse
primer (Table 3), and components of the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystem). The cDNA
equivalent to 25 ng of total RNA for each of the genes was
subjected to q-PCR with gene-specific primers (Table 3) using Fast
SYBR Green Master Mix (AB Applied Biosystem, Carlsbad, CA).
cmeA and glyA primers used for q-PCR were obtained from
previously published studies [55]. Standard curves for the
transcripts of each gene examined were created using a serial
10-fold dilution of 106 to 101 copies of the ATCC 43431 genome.
Based on the known genome size of several C. jejuni strains
deposited at the http://www.xbase.ac.uk/campydb/, the size of
the C. jejuni ATCC 43431genome was estimated to be 1.6
megabases. The expression of all genes investigated was
normalized to glyA previously shown to be unaffected by DCA
[55]. No significant level of DNA contaminant was detected from
all total RNA samples analyzed as determined by q-PCR. All
samples were run in duplicates or triplicates in three independent
experiments.
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Mouse strain and bacterial infection
B6.129P2-IL-10tm1Cgn mice originally from Jackson Laboratories
(Bar Harbor, ME) were bred in house and maintained under
barrier conditions in a facility accredited by the Association for
Assessment and Accreditation of Laboratory Care International.
Mice were free of known murine viruses, Salmonella spp., Citrobacter
rodentium, ecto- and endoparasites, and known Helicobacter spp.
Mice were housed in microisolater, solid-bottomed polycarbonate
cages on hardwood bedding, fed a commercial pelleted diet, and
administered water ad libitum. The mouse protocol was approved
by the MIT Animal Care Committee. Thirty eight mice (19 males
and 19 females) were divided into four experimental groups:
Brucella sham control (4 males and 4 females), WT C. jejuni 43431
(5 males and 5 females), DicmF1 (5 males and 5 females) and
DicmF2 (5 males and 5 females). Six to 7 week old mice were orally
gavaged with either Brucella broth or approximately 108 CFUs of
C. jejuni WT, DicmF1, or DicmF2 suspended in sterilized Brucella
broth. All mice were euthanized by CO2 inhalation at 30 days p.i.
and cecal tissues and fecal samples were aseptically collected for
quantification of C. jejuni by q-PCR to evaluate for C. jejuni
colonization.
Real-time quantitative PCR for C. jejuni in cecum and
feces of IL10-deficient mice
Cecal DNA was isolated using a Roche High Pure PCR
template preparation kit. Fecal DNA was isolated using QIAamp
DNA Stool Mini Kit (Qiagen). C. jejuni ATCC 43431 quantifica-
tion was performed by real time q-PCR using C. jejuni 43431
cytotoxin distending toxin (cdt) A-specific primers (Table 3). The
standard curve for C. jejuni 43431 cdtA was prepared as mentioned
above. cdtA copy numbers of C. jejuni 43431 were expressed per
microgram of murine chromosomal DNA and measured by q-
PCR using a mammalian 18S rRNA gene-based primer and probe
mixture (Applied Biosystems). The assay was run in duplicates.
Statistical analysis
Statistical analysis was performed using student’s t-test or
Mann-Whitney U non-parametric test with p values#0.05
considered as significant. All graphs were generated using
GraphPad Prism 4.0 (GraphPad Software, Inc., LaJolla, CA).
Supporting Information
Figure S1 Confirmation of Dhcp mutants, DicmF mu-
tants, the complemented Dhcp1 strain, and the organi-
zation of hcp and icmF. PCR amplification of genomic DNA
from (A) WT C. jejuni ATCC 43431, isogenic Dhcp1, Dhcp2,
DicmF1, DicmF2 mutants harboring cat , the complemented Dhcp1
strain (Dhcp1(hcp+)), the control hcp1 mutant carrying kat
(Dhcp1(kat)), and (B) isogenic Dhcp3, Dhcp4, Dicmf3, DicmF4 mutants
harboring kat, demonstrating successful replacement of the hcp and
icmF WT alleles with mutant alleles interrupted by the cat (Dhcp1
and Dhcp2: 1350 bp; DicmF1 and DicmF2: 1407 bp) or kat (Dhcp3
and Dhcp4:2079 bp; DicmF3 and DicmF4: 2137 bp) as well as the
complemented PCAT::hcp::kat and the control PCAT::kat into the hcp1
mutant’s 16S–23S rRNA spacer region. (C) Organization and
orientation of hcp and icmF with respect to the neighboring genes in
C. jejuni 43431. Opened triangles represent sites of insertion of cat
and kat. (D) A schematic depiction of the constructs for
complementation of Dhcp1.
(TIF)
Figure S2 Growth and mobility of WT C. jejuni, the
Dhcp1 mutant, the DicmF1 mutant, and the comple-
mented Dhcp1 strain, Dhcp1(hcp+). (A) Growth dynamics of
WT, Dhcp and DicmF mutants, the complemented Dhcp1 strain,
and the Dhcp1 mutant containing only kat integrated in the 16S–
23S spacer region. (B) The swarming ability of WT, the Dhcp
mutant, the DicmF mutant, and the complemented Dhcp1 strain.
The results presented are representative of three independent
experiments.
(TIF)
Figure S3 Growth dynamics of WT C. jejuni, the Dhcp1
mutant, and the DicmF1 mutant in the physiologically
relevant concentrations of DCA. (A) Ten-fold serial dilutions
of overnight cultures were spotted on the agar plates containing
0% to 0.05% DCA and growth was evaluated at 12, 18, 36 and
48 hours. (B) Ten-fold serial dilutions were performed and CFUs
of WT and Dhcp1 mutant were determined at various time points
during growth in liquid media lacking or supplemented with 0.1%
DCA and 0.2% DCA. The results are representative of three
independent experiments. Error bars represent the standard error
of the mean. The data points overlap at multiple time points for
WT and the Dhcp1 mutant. P value: *#0.05, **#0.01.
(TIF)
Figure S4 Expression levels of hcp in WT C. jejuni, the
Dhcp1 mutant, the DicmF1 mutant, and the comple-
mented Dhcp1 strain, Dhcp1(hcp+), grown for 14 hours
in liquid media. The results are representative of three
independent experiments. Error bars represent the standard error
of the mean. P value: ***#0.001.
(TIF)
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